These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 2881443)
21. [Dermal application of lisuride on parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset and on cases with Parkinson's disease]. Nomoto M; Iwata S; Irifune M; Kaseda S; Osame M; Fukuda T Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Jun; 18(3):81-7. PubMed ID: 9800199 [TBL] [Abstract][Full Text] [Related]
22. Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors. Steece-Collier K; Chambers LK; Jaw-Tsai SS; Menniti FS; Greenamyre JT Exp Neurol; 2000 May; 163(1):239-43. PubMed ID: 10785463 [TBL] [Abstract][Full Text] [Related]
23. Toxins and Parkinson's disease: MPTP parkinsonism in humans and animals. Kopin IJ Adv Neurol; 1987; 45():137-44. PubMed ID: 3493621 [No Abstract] [Full Text] [Related]
24. Effects of pramipexole on contraversive rotation and functional motor impairments in 1-methyl-4-phenyl1,2,3, 6-tetrahydropyridine-induced chronic hemiparkinsonian monkeys. Domino EF; Ni L; Zhang H; Kohno Y; Sasa M J Pharmacol Exp Ther; 1998 Dec; 287(3):983-7. PubMed ID: 9864283 [TBL] [Abstract][Full Text] [Related]
25. Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism. Kurlan R; Kim MH; Gash DM Mov Disord; 1991; 6(2):111-8. PubMed ID: 2057003 [TBL] [Abstract][Full Text] [Related]
27. The evolution and distribution of morphological changes in the nervous system of the common marmoset following the acute administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Gibb WR; Terruli M; Lees AJ; Jenner P; Marsden CD Mov Disord; 1989; 4(1):53-74. PubMed ID: 2494438 [TBL] [Abstract][Full Text] [Related]
28. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease. Jenner P; Marsden CD J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760 [TBL] [Abstract][Full Text] [Related]
29. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset. Jenner P; Rupniak NM; Rose S; Kelly E; Kilpatrick G; Lees A; Marsden CD Neurosci Lett; 1984 Sep; 50(1-3):85-90. PubMed ID: 6436758 [TBL] [Abstract][Full Text] [Related]
30. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. Nash JE; Fox SH; Henry B; Hill MP; Peggs D; McGuire S; Maneuf Y; Hille C; Brotchie JM; Crossman AR Exp Neurol; 2000 Sep; 165(1):136-42. PubMed ID: 10964492 [TBL] [Abstract][Full Text] [Related]
31. [Parkinsonism and MPTP (methylphenyltetrahydropyridine)]. Nagatsu T No To Shinkei; 1986 Jul; 38(7):706-7. PubMed ID: 3489476 [No Abstract] [Full Text] [Related]
32. Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys. Schneider JS; Pope-Coleman A; Van Velson M; Menzaghi F; Lloyd GK Mov Disord; 1998 Jul; 13(4):637-42. PubMed ID: 9686767 [TBL] [Abstract][Full Text] [Related]
33. Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors. Gomez-Mancilla B; Boucher R; Gagnon C; Di Paolo T; Markstein R; Bédard PJ Mov Disord; 1993 Apr; 8(2):144-50. PubMed ID: 8474480 [TBL] [Abstract][Full Text] [Related]
34. Study on MPTP-induced parkinsonian animal model in rhesus monkey and the mechanism of MPTP. Chen SD; Xu DL; Yu HZ; Tang QM; Xu XR; Wang ZG; Liang PF Chin Med J (Engl); 1988 Dec; 101(12):879-83. PubMed ID: 3150735 [No Abstract] [Full Text] [Related]
35. Endogenous analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: indoleamine derived tetrahydro-beta-carbolines as potential causative factors in Parkinson's disease. Collins MA; Neafsey EJ; Cheng BY; Hurley-Gius K; Ung-Chhun NA; Pronger DA; Christensen MA; Hurley-Gius D Adv Neurol; 1987; 45():179-82. PubMed ID: 3493625 [No Abstract] [Full Text] [Related]
36. [A model of Parkinson's disease: effect of L-dopa therapy on movement parameters and electromyographic activity in monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)]. Doudet D; Gross C; Lebrun-Grandié P; Bioulac B C R Seances Soc Biol Fil; 1985; 179(1):85-97. PubMed ID: 3161601 [TBL] [Abstract][Full Text] [Related]
37. Olfactory impairment and Parkinson's disease-like symptoms observed in the common marmoset following administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Miwa T; Watanabe A; Mitsumoto Y; Furukawa M; Fukushima N; Moriizumi T Acta Otolaryngol Suppl; 2004 Aug; (553):80-4. PubMed ID: 15277042 [TBL] [Abstract][Full Text] [Related]
39. Effects of classical and novel agents in a MPTP-induced reversible model of Parkinson's disease. Close SP; Elliott PJ; Hayes AG; Marriott AS Psychopharmacology (Berl); 1990; 102(3):295-300. PubMed ID: 1979176 [TBL] [Abstract][Full Text] [Related]
40. Saccade responses to dopamine in human MPTP-induced parkinsonism. Hotson JR; Langston EB; Langston JW Ann Neurol; 1986 Oct; 20(4):456-63. PubMed ID: 3491578 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]